Coming soon: A vaccine against Mastitis
Published: June 30, 2016
Source : www.usherbrooke.ca
For more than seven years, Professor François Malouin has been developing a vaccine against bovine mastitis. Now, the result of that research is a license agreement with the multinational Bayer that may well revolutionize the dairy industry around the world.
The Université de Sherbrooke (UdeS) is proud to announce that its research commercialization firm TransferTech Sherbrooke has signed a license agreement with the multinational Bayer to finalize the development of a vaccine against bovine mastitis, one of the most harmful endemic diseases for dairy herds around the world. The impact of the disease costs billions of dollars annually.
Bovine mastitis in brief
Bovine mastitis is an inflammation of the mammary gland in cows, generally caused by a bacterial infection. Staphylococcus aureus is most often the bacteria culprit. It is contagious, transmitting easily from one cow to another in a herd. It causes persistent and chronic infections, which can last for months.
The economic impact of bovine mastitis on dairy production is enormous: in the order of $110 million per year in Quebec and $400 million across Canada.
Developed by Professor François Malouin and his team at the Université de Sherbrooke’s Department of Biology, the vaccine offers a previously unexplored approach to controlling proliferation of the infection, which is caused by the very virulent Staphylococcus aureus bacteria.
“Our partners at Bayer immediately recognized the vaccine’s potential,” said Professor Malouin. “For this reason, the company became involved in finalizing its development and, possibly, commercializing it in the next few years.”
UdeS welcomes the opportunity to partner with Bayer to advance research on bovine mastitis, a problem on which many other teams are working around the world. “This is eloquent proof of the quality of research produced in our laboratories,” said Jacques Beauvais, Vice-President of Research, Innovation, and Entrepreneurship at the Université de Sherbrooke.
Major support for the institutional strategy
In addition, this agreement fits perfectly with the Université de Sherbrooke’s innovation, partnership, and entrepreneurship strategy. “We want to demonstrate that our exploratory research can lead to very concrete benefits, with practical applications that have positive results for the public,” said Mr. Beauvais.
This discovery would not have been possible without the contribution of Céline Ster, Marianne Allard, and Julie Côté Gravel (Université de Sherbrooke), the collaboration of scientists from the Université de Montréal’s Faculty of Veterinary Medicine and from Agriculture and Agri-Food Canada, particularly Pierre Lacasse, and funding from the Canadian Bovine Mastitis and Milk Quality Research Network.
Source
www.usherbrooke.caRelated topics:
Recommend
Comment
Share
4 de julio de 2016
Great efforts and wish him good luck in his future endavours
Recommend
Reply
5 de julio de 2016
Dear Sir ,
I would like to inform you that clinical mastitis is easily induced and treated effectively 100 % within 24 - 36 hours for acute type and within 7- 9 days for peracute mastitis. . To be a pioneer in chemotherapy of bovine mastitis you must know pharmacology of A.N.S.,antibiotic and non antibiotics , autacoids, anti-histaminics, anti-inflammatory , locally acting drugs, drug residues, routes of drug administration , water and electrolyte pharmacology up to 70 % of the syllabus of veterinary pharmacology . That was concluded because there is no immunity in the udder . Moreover, some recommendations in treatment of clinical mastitis reported in some recent text books failed to treat this infection and lead to loss of the quarter.
Recommend
Reply
4 de julio de 2016
Good it is positive effort against bovine mastitis, I hope after few years we defeat the economic loss which is due to mastitis infection.
Recommend
Reply
3 de julio de 2016
it is great that Professor Francois Malouin has been succeeded to make such important vaccine, but the level of the immunity could be considered, the farmers will not ignore udder care and hygiene.
thanks .
Dr. Abdul Qader Samsor
Recommend
Reply
1 de julio de 2016
What about other bacterial causes,would this vaccine be a combination or only for staph.
Recommend
Reply
1 de julio de 2016
PLEASE I want to ask about When this vaccine will be available in commercial market ?
Recommend
Reply
Would you like to discuss another topic? Create a new post to engage with experts in the community.
Featured users in Dairy Cattle
